Radiesse

Record type

Source-linked family profile

Recorded maker

Merz Aesthetics

Classification

Dermal fillerSkin booster / biostimulator

Material identity

calcium hydroxylapatite

Snapshot date

14 August 2026

Manufacturer and category are catalogue fields. They are not, by themselves, a regulatory classification or verification of the exact marketed presentation.

Product names and regulatory context do not travel automatically between countries. Each row below is limited to its named source market.

• Radiesse

  Merz · Skin booster / biostimulator

• Radiesse Lidocaine

  Merz · Skin booster / biostimulator

  →

1. Instructions for use

   1. Radiesse injectable implant — instructions for use

   U.S. Food and Drug Administration · United States

   Open source ↗

   Supports: Named product identity and calcium-hydroxylapatite material description for the labelled presentation.

2. Regulator

   2. FDA-approved dermal fillers

   U.S. Food and Drug Administration · United States

   Open source ↗

   Supports: Regulatory-method context and the requirement to verify individual filler records and labels.

3. Regulator

   3. RADIESSE injectable implant — PMA P050052

   U.S. Food and Drug Administration · United States

   Open source ↗

   Supports: The US Radiesse PMA family and supplement record for an aesthetic dermal implant.

1. 1

   Identity

   Radiesse is documented in the US as an injectable implant family with a PMA supplement history.

   Scope: The statement does not treat every supplement or catalogue variant as the same presentation.

   Evidence: Radiesse injectable implant — instructions for useEvidence: RADIESSE injectable implant — PMA P050052
2. 2

   Material / active name

   The current FDA-hosted IFU describes calcium-hydroxylapatite microspheres in an aqueous gel carrier.

   Scope: Material identity for the cited US presentation only.

   Evidence: Radiesse injectable implant — instructions for use

Use boundary

What this record does not establish

• Regulatory statusOnly within a source's named jurisdiction; family-profile review does not establish status elsewhere.
• Authenticity or supply chainA catalogue name cannot authenticate an individual box, lot, or seller.
• Clinical suitabilityNo product selection, patient assessment, dose, protocol, or injection technique is provided.
• Availability or equivalenceNames, formulations, units, and presentations can vary by market and over time.